HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fraudulent Zika Claims Are CDER's Latest Extermination Target

This article was originally published in The Tan Sheet

Executive Summary

CDER is on the lookout for companies seeking to capitalize off the Zika health crisis with fraudulent claims about their products’ ability to treat or prevent the disease, says Brad Price, acting director of the Division of Nonprescription Drugs and Health Fraud, Office of Compliance.

Advertisement

Related Content

Mosquito Repellent Promotion Tumbles On Undisclosed Paid Social Media Plugs By US Olympic Gymnasts
Crackdown On Illegal Online Pharmacies Like Playing Internet 'Whack-A-Mole'
Crackdown On Illegal Online Pharmacies Like Playing Internet 'Whack-A-Mole'
Health & Wellness Industry News Roundup: Week Of Aug. 1
FDA Examination Of Homeopathic Regulation Looks Beyond Safety History
Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements
FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims

Topics

Advertisement
UsernamePublicRestriction

Register

RS108930

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel